{"symbol":"REGN","fiscalQuarter":"Q4-2024","reportDate":"2025-02-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2024","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.53%","keyNumbers":[{"metric":"EPS","actual":"$12.07","expected":"N/A","surprise":"+25.51%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["Management highlighted strong performance in key product areas.","They expressed optimism about future growth opportunities."],"summary":"Overall, management conveyed a positive outlook despite not providing specific guidance. They emphasized the strength of their product pipeline."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance, exceeding expectations by over 25%, likely reflects effective cost management and robust sales in its product lines. The stock rose by 4.53% following the announcement, indicating investor confidence in the company's future prospects. However, the lack of revenue data and guidance leaves some uncertainty about the overall financial picture.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2024 earnings: EPS beat expectations. Stock up 4.53%. Full breakdown."}}